Innocan Pharma Corporation closes $8.2 million private placement with institutional investors

1 minute read
13 October 2021

On October 13, 2021, Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced that it had closed its previously announced private placement of common shares and warrants to purchase common shares to institutional investors for aggregate gross proceeds to the company of $8,227,150 million. A.G.P./Alliance Global Partners acted as the exclusive placement agent for the private placement.

Innocan, together with its wholly-owned subsidiary, Innocan Pharma Ltd. (Innocan Israel), is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD.

Gowling WLG advised Innocan with respect to this private placement with a team that included Jason A. Saltzman, Frank Sur, Josh Rosen and Joseph McDonald.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.